Mode
Text Size
Log in / Sign up
N/A N=252 Randomized Double-blind Treatment

Evaluation of a Novel Device for Treatment of Migraine Headache

Migraine Without Aura · Migraine With Aura

Enrolled (actual)
252
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nerivio Migra-1 active device (Device); Nerivio Migra-1 Sham device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Theranica
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment
66; 40
SECONDARY
Percentage of Participants With Reduction of Most Bothersome Migraine-associated Symptom (MBS) Relief at 2 Hours Post Treatment
44; 22
SECONDARY
Percentage of Participants With Reduced Migraine Headache AND MBS Relief at 2 Hours Post Treatment
38; 15
SECONDARY
Percentage of Participants With Pain Disappearance at 2 Hours Post Treatment
37; 19

Summary

Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment. Recent evidence suggests that electro stimulation is effective in providing relief for chronic headaches including migraine. It is tolerable by patients and associated with no adverse effects. The device utilizes electro stimulation to achieve conditioned pain modulation (CPM). CPM an stimulate endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere. This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications. The study objectives is to demonstrate the safety and effectiveness of the Nerivio Migra electro stimulation device for the reduction of migraine headache during an attack of migraine with or without aura. The study is intended for subject with 2-8 migraine episodes per month. patients will receive the device, either an active or a placebo type, and will be asked to use the device at home or in any location that they will be when the migraine starts. The study hypothesis is that electro stimulation delivered transcutaneously to the peripheral nervous system at onset of a migraine attack significantly reduce headache pain demonstrated by a significant difference between proportions of responders to the active treatment stimulation in comparison to proportion of responders that will use a placebo device.

Eligibility Criteria

Inclusion Criteria

  • Subjects age 18-75 years old.
  • Subjects meet the ICHD-3 diagnostic criteria for migraine with or without aura
  • Subjects report 2-8 migraine attacks per month.
  • Stable migraine preventive medications in the last two months prior to recruitment (No change in usage or dosage).
  • Subjects must be able and willing to comply with the protocol
  • Subjects must be able and willing to provide written informed consent

Exclusion Criteria

  • Subject has other significant pain, medical or psychologic problems that in the opinion of the investigator may confound the study assessments
  • Subject has an implanted electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).
  • Subject has known uncontrolled epilepsy.
  • Any use of Cannabis including medical use.
  • Subject has >10 headache days per month.
  • Subject has undergone nerve block (occipital or other) in the head or neck within the last 2 weeks.
  • Subject is participating in any other clinical study.
  • The subject does not have the basic cognitive and motor skills needed to operate a smartphone.
  • Pregnant, or trying to get pregnant
  • Subject is experiencing a menstrually related migraine
  • Received OnabotulinumtoxinA or any botulinum toxin injections for migraine within the previous month
  • Received parenteral infusions for migraine within the previous 2 weeks.
  • Subject participated in a previous study with the Nerivio Migra 1 device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03361423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search